標(biāo)題: Titlebook: Circulating Tumor Cells; Advances in Liquid B Richard J. Cote,Evi Lianidou Book 2023Latest edition The Editor(s) (if applicable) and The Au [打印本頁] 作者: Autonomous 時(shí)間: 2025-3-21 16:32
書目名稱Circulating Tumor Cells影響因子(影響力)
作者: trigger 時(shí)間: 2025-3-21 23:59 作者: 不能仁慈 時(shí)間: 2025-3-22 02:06 作者: 玩忽職守 時(shí)間: 2025-3-22 06:03
Development and Validation of Molecular Assays for Liquid Biopsy Applicationsling till the final results on the molecular biomarkers detected in CTCs. Development of standards for quality control of CTC analysis and interlaboratory ring studies are urgently needed. Toward this a joint and well-coordinated effort of researchers, clinicians, and technology providers is highly 作者: maculated 時(shí)間: 2025-3-22 12:42 作者: 放肆的我 時(shí)間: 2025-3-22 15:10 作者: 放肆的我 時(shí)間: 2025-3-22 20:28
Insight into Intratumoral Heterogeneity Through Single CTC Sequencing and CDX Analysis and genetic characterization of a neuroendocrine trans-differentiation castration-resistant prostate cancer (CRPC) CTC-derived xenograft (CDX) model. This CDX model represents a unique tool to improve our understanding of lineage plasticity and genetic mechanisms driving therapeutic resistance in C作者: ENDOW 時(shí)間: 2025-3-23 00:50
Molecular Characterization of Single Circulating Tumor Cells in Breast and Ovarian Cancer predictive factors. Promising candidates are circulating tumor cells (CTCs), circulating DNA, microRNAs, as well as extracellular vesicles, all discussed to reflect the “real-time biopsy” at a certain time point of the disease. Liquid biopsy analysis allows rapid and repeated sampling and sequentia作者: Adrenaline 時(shí)間: 2025-3-23 04:43 作者: cruise 時(shí)間: 2025-3-23 09:34 作者: 正常 時(shí)間: 2025-3-23 10:40
Regulatory Diffusion from Europe to Asia03)..Thomas Ashworth discovered in 1869 that distant metastatic spread occurs through the circulatory system (Ashworth, 14:146, 1869). This discovery was made through a microscopic observation of cells with similar morphology to the primary tumor found in blood of a man with metastatic disease (Ashw作者: Grievance 時(shí)間: 2025-3-23 16:16
Yasushi Ueki,Etsuyo Michida,Kaoru Nabeshimaling till the final results on the molecular biomarkers detected in CTCs. Development of standards for quality control of CTC analysis and interlaboratory ring studies are urgently needed. Toward this a joint and well-coordinated effort of researchers, clinicians, and technology providers is highly 作者: 強(qiáng)行引入 時(shí)間: 2025-3-23 20:17 作者: 鉆孔 時(shí)間: 2025-3-24 00:45
,Die Methode der Regulationsprüfung,tastasis (BCBM) possess increased Notch signaling and immune-evasion pathways. Second, we generated an in vivo model of clinical metastatic dormancy by the systemic injection of CTC-enriched cell populations in immunodeficient mice (NSG), which revealed that mTOR signaling maintains dormancy in bone作者: 多樣 時(shí)間: 2025-3-24 03:10 作者: 注射器 時(shí)間: 2025-3-24 10:23 作者: jovial 時(shí)間: 2025-3-24 11:19 作者: Aprope 時(shí)間: 2025-3-24 18:18
2199-2584 ,and have been established as an important evaluative and research tool in advanced cancer, and potentially important in early stage disease. CTC defines tumor cells circulating in blood, while Disseminated Tum978-3-031-22903-9Series ISSN 2199-2584 Series E-ISSN 2199-2592 作者: 審問,審訊 時(shí)間: 2025-3-24 19:34 作者: 表示問 時(shí)間: 2025-3-25 00:34 作者: 諄諄教誨 時(shí)間: 2025-3-25 06:17 作者: BACLE 時(shí)間: 2025-3-25 11:05 作者: 有發(fā)明天才 時(shí)間: 2025-3-25 14:47 作者: incisive 時(shí)間: 2025-3-25 18:08
https://doi.org/10.1007/978-981-10-8062-3astatic process and guide cancer patient care more effectively. Here, we will review what we have learned from CTC and tdEV identified by the CellSearch system and discuss our initial attempts to further characterize tdEV and explore their potential.作者: optional 時(shí)間: 2025-3-25 23:28
CTC-Based Liquid Biopsies and Diagnostic Leukapheresisiple, first applications, and current challenges of diagnostic leukapheresis (DLA) to collect CTCs from large blood volumes, enhancing CTC detection and analysis for research and potential clinical applications.作者: CAB 時(shí)間: 2025-3-26 04:00
Translational Opportunities of Extracellular Vesicles in Biomedicinehysical characterization and for their cargo assays (protein, nucleic acids, lipids). We will also comment on their potential translation as cancer biomarkers, fundamental research challenges, and their comparison with other circulating markers.作者: 同音 時(shí)間: 2025-3-26 04:46 作者: ABASH 時(shí)間: 2025-3-26 10:05
Book 2023Latest editionishing molecular targets, evaluating the efficacy of therapy, detecting the earliest signs of recurrence, and even detecting cancer at its earliest and most curable stages. The analysis of cancer through blood samples is now known as the liquid biopsy and has been a rich source of research and clini作者: Amylase 時(shí)間: 2025-3-26 13:10 作者: jet-lag 時(shí)間: 2025-3-26 19:29 作者: ANNUL 時(shí)間: 2025-3-26 22:46 作者: 暫停,間歇 時(shí)間: 2025-3-27 02:39
Exploiting Exosomes for Cancer Diagnosis and Treatmentry systems for cancer treatment. In biomedical research, the translational potential of exploiting exosomes for cancer diagnosis and treatment is increasingly appreciated and is the focus of discussion in this chapter.作者: mutineer 時(shí)間: 2025-3-27 06:14
Capture and Concentration of Circulating Cancer-Associated Extracellular Vesiclesose significant challenges in separating tumor-derived EVs (tdEV) from high background of healthy cell-derived EVs in peripheral blood. Here we discussed the recent technology advancements in the field of enriching subpopulations of EVs from bulk populations, with a focus on tdEV enrichment for cancer liquid biopsy purposes.作者: 指令 時(shí)間: 2025-3-27 13:07 作者: nutrients 時(shí)間: 2025-3-27 15:19
Richard J. Cote,Evi LianidouExpands technology focus on topics related to CTC/DTC, ctDNA/RNA and ctExosomes.Comprehensive resource for the liquid biopsy field.Addresses up-to-the-minute studies on the latest advances in the liqu作者: Magisterial 時(shí)間: 2025-3-27 20:10 作者: mediocrity 時(shí)間: 2025-3-27 23:58 作者: 縮短 時(shí)間: 2025-3-28 03:26 作者: GLADE 時(shí)間: 2025-3-28 09:56 作者: 不要嚴(yán)酷 時(shí)間: 2025-3-28 13:39
Ethics in Health Sector: Global Approachision-making. The full potential of CTCs for such liquid biopsies is currently limited by their low-frequency and unreliable detection even in metastatic cancer patients. A major reason for the low detection frequency is the low volume of a conventional blood sample not representative for the total 作者: FLOAT 時(shí)間: 2025-3-28 17:02 作者: hypertension 時(shí)間: 2025-3-28 20:48 作者: Legend 時(shí)間: 2025-3-29 00:17 作者: 群居男女 時(shí)間: 2025-3-29 06:54 作者: 賠償 時(shí)間: 2025-3-29 08:41 作者: 松軟 時(shí)間: 2025-3-29 13:08 作者: Physiatrist 時(shí)間: 2025-3-29 16:13 作者: 弄臟 時(shí)間: 2025-3-29 22:25
Yasushi Ueki,Etsuyo Michida,Kaoru Nabeshimater, we are focusing on the development and validation of molecular assays for CTC analysis and present the principles of the main technologies used for CTC enrichment, isolation, and detection. We focus on the main principles and applications of molecular assays used for CTC molecular characterizat作者: micronized 時(shí)間: 2025-3-30 03:21
G?knur Büyükkara,Onur Enginar,Hüseyin Temizhe seeds for metastatic nodules. Given the unique role of CTCs, the study of this cell population could enable significant strides in understanding metastasis. The clinical importance of CTCs for predicting overall survival has been routinely demonstrated. Recently, advancements in culturing and exp作者: 同音 時(shí)間: 2025-3-30 05:39 作者: 整潔 時(shí)間: 2025-3-30 09:14
Regulationsprüfung des Kreislaufs by phenotypic plasticity. Hematogenous dissemination of circulating tumor cells (CTCs) is considered as the major form of metastatic spread to distant organs. Genomic and functional characterization of CTCs may provide insight into the biology of cancer cells that promote metastases formation and p作者: Thyroiditis 時(shí)間: 2025-3-30 14:53
,Exzessives Schreien des S?uglings,tly at advanced stages, resulting in a challenging treatment situation and a generally poor outcome. Radical tumor debulking, followed by platinum-based chemotherapy with/without bevacizumab, is the treatment of choice; however, the majority of patients will ultimately relapse due to the development作者: 大范圍流行 時(shí)間: 2025-3-30 17:01
